## Suzanne M D'addio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5489270/publications.pdf

Version: 2024-02-01

687363 996975 15 848 13 15 citations h-index g-index papers 15 15 15 1331 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Controlling drug nanoparticle formation by rapid precipitation. Advanced Drug Delivery Reviews, 2011, 63, 417-426.	13.7	317
2	Effects of block copolymer properties on nanocarrier protection from in vivo clearance. Journal of Controlled Release, 2012, 162, 208-217.	9.9	81
3	Optimization of cell receptor-specific targeting through multivalent surface decoration of polymeric nanocarriers. Journal of Controlled Release, 2013, 168, 41-49.	9.9	67
4	Constant size, variable density aerosol particles by ultrasonic spray freeze drying. International Journal of Pharmaceutics, 2012, 427, 185-191.	5.2	63
5	Aerosol Delivery of Nanoparticles in Uniform Mannitol Carriers Formulated by Ultrasonic Spray Freeze Drying. Pharmaceutical Research, 2013, 30, 2891-2901.	3.5	55
6	In Situ Characterization of Pharmaceutical Formulations by Dynamic Nuclear Polarization Enhanced MAS NMR. Journal of Physical Chemistry B, 2017, 121, 8132-8141.	2.6	51
7	Protected Peptide Nanoparticles: Experiments and Brownian Dynamics Simulations of the Energetics of Assembly. Nano Letters, 2009, 9, 2218-2222.	9.1	44
8	Novel Method for Concentrating and Drying Polymeric Nanoparticles: Hydrogen Bonding Coacervate Precipitation. Molecular Pharmaceutics, 2010, 7, 557-564.	4.6	34
9	Inhibition of N-Nitrosamine Formation in Drug Products: A Model Study. Journal of Pharmaceutical Sciences, 2021, 110, 3773-3775.	3.3	33
10	Novel methods of targeted drug delivery: the potential of multifunctional nanoparticles. Expert Review of Clinical Pharmacology, 2009, 2, 265-282.	3.1	27
11	New and Evolving Techniques for the Characterization of Peptide Therapeutics. Journal of Pharmaceutical Sciences, 2016, 105, 2989-3006.	3.3	26
12	Antitubercular Nanocarrier Combination Therapy: Formulation Strategies and <i>in Vitro</i> for Rifampicin and SQ641. Molecular Pharmaceutics, 2015, 12, 1554-1563.	4.6	22
13	Determining drug release rates of hydrophobic compounds from nanocarriers. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2016, 374, 20150128.	3.4	17
14	Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral Dosing. Journal of Medicinal Chemistry, 2022, 65, 6001-6016.	6.4	8
15	Antimicrobial Excipient-Induced Reversible Association of Therapeutic Peptides in Parenteral Formulations. Journal of Pharmaceutical Sciences, 2021, 110, 850-859.	3.3	3